Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Rating Changes as of May 17, 2018

May 17, 2018 - By Nicole Mills

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

In total 2 analysts cover Collegium Pharmaceutical (NASDAQ:COLL). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:COLL)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. In Tuesday, January 23 report Piper Jaffray maintained the stock with “Buy” rating. On Sunday, February 11 the rating was maintained by Jefferies with “Buy”. In Thursday, December 7 report Piper Jaffray maintained it with “Buy” rating and $24.0 target. On Thursday, December 14 the firm earned “Buy” rating by Piper Jaffray. On Wednesday, November 29 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has “Buy” rating given by Piper Jaffray. On Monday, February 12 the stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Piper Jaffray. Listed here are Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PTs and latest ratings.

12/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
11/02/2018 Broker: Jefferies Rating: Buy New Target: $32.0 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $33.0 Maintain
14/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $23.0 Maintain
07/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $24.0 Maintain
29/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $19.0 Maintain

Ticker’s shares touched $25.1 during the last trading session after 2.20% change.Currently Collegium Pharmaceutical, Inc. is uptrending after 133.98% change in last May 17, 2017. COLL has 186,789 shares volume. COLL outperformed the S&P 500 by 122.43%.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is valued at $829.40 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news brought out briefly go to: Globenewswire.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Collegium Reports First Quarter Financial Results and Provides Corporate Update” brought out on May 09, 2018, “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018, “FDA OKs first non-opioid treatment for opioid withdrawal” with a publish date: May 16, 2018, “Collegium Pharmaceutical’s (COLL) CEO Michael Heffernan on Q1 2018 Results – Earnings Call Transcript” and the last “Why Depomed Inc.’s Shares Soared 23.2% Higher” with publication date: May 10, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.